Treatment & control of excessive bleeding in various surgical & medical conditions including general surgical cases, prostatectomy; menorrhagia/menometrorrhagia, postpartum hemorrhage, abortion, conisation of the cervix; epistaxis, hemoptysis, PUD w/ hemorrhage, hematuria, blood dyscrasias w/ hemorrhage, hereditary angioneurotic edema; tooth extraction & dental surgery.
General surgical cases 1-1.5 g every 6-8 hr. Prostatectomy 1-1.5 g every 6-8 hr until macroscopic hematuria is no longer present. Menorrhagia/menometrorrhagia 1-1.5 g every 6-8 hr for 3-4 days. Postpartum hemorrhage 1-1.5 g every 6-8 hr. Conisation of the cervix 1.5 g every 8 hr for 12-14 days after surgery. Epistaxis 1.5 g every 8 hr for 4-10 days. GI hemorrhage 1.5 g every 6 hr, max of 4 days. Hematuria 1-1.5 g every 8-12 hr daily until macroscopic hematuria is no longer present. Hereditary angioneurotic edema 1-1.5 g every 8-12 hr as intermittent or continuous treatment depending on the prodromal symptoms of the patient. Dental surgery in patient w/ coagulopathies 1-1.5 g every 6-8 hr for 6-8 days after surgery. Childn 25 mg/kg/dose bid or tid, depending on the indication. Renal insufficiency serum creatinine >5.66 mg/dL 15 mg/kg every 48 hr or 7.5 mg every 24 hr, 2.83-5.66 mg/dL 15 mg/kg bid, 1.36-2.83 mg/dL 15 mg/kg bid.
View Hemanex overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Active thromboembolic disease (eg, DVT, pulmonary embolism, cerebral thrombosis). History of thrombosis or thromboembolism (eg, retinal vein or artery occlusion) or intrinsic risk of thrombosis or thromboembolism (eg, thrombogenic valvular disease, thrombogenic cardiac rhythm disease, hypercoagulopathy). Concomitant use w/ thrombin. Discontinue if disturbance of color vision arise during the course of therapy. Subarachnoid hemorrhage.
Perform ophth exam before & at regular intervals during treatment. Not indicated in hematuria caused by diseases of the renal parenchyma. Urinary tract obstruction due to clot formation in patients w/ severe bleeding from the upper urinary tract. High risk of thrombosis (previous thromboembolic event & family history of thromboembolic disease). Concomitant use w/ hormonal contraception. Disseminated intravascular coagulation. Irregular menstrual bleeding. Indissoluble clots may develop in body cavities eg, pleural & joint spaces. Not recommended for women taking either factor IX complex concentrates or anti-inhibitor coagulant concentrates. Cerebral edema & cerebral infarction in women w/ subarachnoid hemorrhage. Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction. Convulsion. Renal insufficiency. Pregnancy & lactation. Childn. Elderly.
May cause thromboembolism w/ batroxobin. Coagulation may be further activated w/ coagulation factor agents (eg, Eptacog-alfa). May cause thrombosis w/ hemocoagulase. May counteract the thrombolytic effect of fibrinolytic prep. May decrease the efficacy w/ tissue plasminogen activators.
Sign Out
